ZAI LAB LIMITED Payments to Acquire Equity Method Investments
ZAI LAB LIMITED (ZLAB) reported Payments to Acquire Equity Method Investments of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireEquityMethodInvestments · last filed 2024-02-27
- ZAI LAB LIMITED payments to acquire equity method investments for the quarter ending 2022-12-31 was $0.00.
- ZAI LAB LIMITED payments to acquire equity method investments for the quarter ending 2021-12-31 was $0.00.
- ZAI LAB LIMITED payments to acquire equity method investments for the quarter ending 2018-12-31 was $29.30K.
- ZAI LAB LIMITED payments to acquire equity method investments for fiscal 2023 was $0.00.
- ZAI LAB LIMITED payments to acquire equity method investments for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- ZAI LAB LIMITED payments to acquire equity method investments for fiscal 2021 was $30.00M.
- ZAI LAB LIMITED payments to acquire equity method investments for fiscal 2020 was $0.00.
| Period end | Payments to Acquire Equity Method Investments 3 month | Payments to Acquire Equity Method Investments 9 month | Payments to Acquire Equity Method Investments 12 month | Payments to Acquire Equity Method Investments 12 month as first filed |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-27 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 10-K · filed 2024-02-27 | ||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-09 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $30.00M 10-K · filed 2024-02-27 | ||
| 2021-09-30 | $30.00M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-01 | |||
| 2018-12-31 | $29.30K derived: 10-K 12 month − 6-K 9 month · filed 2021-03-01 | $2.09M 10-K · filed 2021-03-01 | $2.09M 20-F · filed 2019-03-29 | |
| 2018-09-30 | $2.06M 6-K · filed 2020-01-21 | |||
| 2017-12-31 | $1.90M 20-F · filed 2020-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |